BURLINGTON, Mass. / Mar 01, 2023 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will participate in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place in Boston, MA on March 6-8, 2023. Heather Getz, Executive Vice President & Chief Financial Officer, Darius Shahida, Chief Strategy Officer & Chief Business Development Officer, and Dr. John Martin, Chief Medical Officer will participate in a fireside chat on March 7, 2023 at 2:10 pm Eastern Time.
A live webcast of the presentation will be available in the Events & Presentations section of the Butterfly Network investor website.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased today by trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, North America and South America; to learn more about available countries, visit: butterflynetwork.com/choose-your-country. Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.
Last Trade: | US$2.35 |
Daily Change: | -0.21 -8.20 |
Daily Volume: | 2,920,800 |
Market Cap: | US$437.450M |
November 01, 2024 October 08, 2024 September 17, 2024 August 01, 2024 June 27, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB